In vitro and in vivo studies showed that blocking CD47-SIRPα interaction by using anti-CD47 mAbs enhanced macrophage-mediated phagocytosis, improved survival, and reduced tumor burden in human GBM engrafted mice.4 The gene discussed is CD47; the disease is glioblastoma.